Literature DB >> 7794549

HIV-1 V3 envelope sequences required for macrophage infection.

T Henkel, P Westervelt, L Ratner.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7794549

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  6 in total

1.  Characterisation of near-full length genome sequences of three South African human immunodeficiency virus type 1 subtype C isolates.

Authors:  Gillian M Hunt; Maria A Papathanasopoulos; Glenda E Gray; Caroline T Tiemessen
Journal:  Virus Genes       Date:  2003-01       Impact factor: 2.332

2.  Identification of conserved and variable structures in the human immunodeficiency virus gp120 glycoprotein of importance for CXCR4 binding.

Authors:  Stéphane Basmaciogullari; Gregory J Babcock; Donald Van Ryk; Woj Wojtowicz; Joseph Sodroski
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

3.  Involvement of both the V2 and V3 regions of the CCR5-tropic human immunodeficiency virus type 1 envelope in reduced sensitivity to macrophage inflammatory protein 1alpha.

Authors:  Y Maeda; M Foda; S Matsushita; S Harada
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

4.  Analysis of the critical domain in the V3 loop of human immunodeficiency virus type 1 gp120 involved in CCR5 utilization.

Authors:  C S Hung; N Vander Heyden; L Ratner
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

5.  CD4-induced T-20 binding to human immunodeficiency virus type 1 gp120 blocks interaction with the CXCR4 coreceptor.

Authors:  Wen Yuan; Stewart Craig; Zhihai Si; Michael Farzan; Joseph Sodroski
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

6.  Mapping of the CXCR4 binding site within variable region 3 of the feline immunodeficiency virus surface glycoprotein.

Authors:  Magnus Sundstrom; Rebecca L White; Aymeric de Parseval; K Jagannadha Sastry; Garrett Morris; Chris K Grant; John H Elder
Journal:  J Virol       Date:  2008-07-02       Impact factor: 5.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.